ResMed, Inc. Stock Hits New 52-Week Low at USD 211.93

ResMed, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 211.93 on April 29, 2026. This significant price point reflects a notable shift in the stock's performance, particularly when compared to its 52-week high of USD 293.81. Over the past year, ResMed's stock has shown a modest performance increase of 0.13%, which stands in stark contrast to the S&P 500's impressive gain of 28.33%. The company's market capitalization is currently valued at USD 43,243 million, and it maintains a price-to-earnings (P/E) ratio of 29.00. In terms of financial health, ResMed boasts a return on equity of 23.77% and a dividend yield of 3.17%. The company's debt-to-equity ratio is reported at -0.12, indicating a strong balance sheet. As the stock navigates this low point, it highlights the ongoing dynamics within the pharmaceuticals and biotechnology industry.